FDA Grants Breakthrough Device Designation for CRISPR Blood Test for Tuberculosis
IntelliGenome’s CRISPR-TB Blood Test, designed to detect Mycobacterium tuberculosis cfDNA, received FDA Breakthrough Device Designation.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
